A first-in-class biotherapeutic
PB01 is recombinant human follistatin-288, the most potent form of follistatin. It is a novel biological molecule with strong anti-inflammatory and anti-fibrotic actions. PB01 binds to and neutralizes the activity of the TGFβ superfamily of growth and differentiation cytokines, most notably the activin family. Follistatin has been shown to reduce inflammation, oxidative stress and cell death, and enhance tissue repair in preclinical models of acute kidney injury.
Paranta is developing PB01 for therapeutic use in the prevention of delayed graft function during kidney transplantation.Read More
Paranta is focused on developing PB01 for the prevention of delayed graft function during kidney transplantation.
Patents granted in US, Europe and Australia covering method of reducing graft dysfunction in organ transplantation (expiry 2033); pending Canada. Patents pending US, Canada, Europe and Australia on method of reducing acute kidney injury induced by platinum chemotherapy. Provisional patents pending on PB01 manufacture.